Edwards Lifesciences Corp, founded in 1958 and headquartered in Irvine, California, is a global leader in providing innovative solutions for heart valve and critical care monitoring. The company specializes in transcatheter heart valves, surgical heart valves, and hemodynamic monitoring systems, aiming to enhance patient care through scientifically advanced technologies.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| EW 4.30% 2028-06-15 USDEdwards Lifesciences Corp | United States | 2028-06-15 | 4.300 | 4.16 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Edwards Lifesciences began issuing corporate bonds in 2005 to support its growth strategies and fund research and development. Notable issuances include the $1 billion bond offering in 2020, which helped finance the expansion of its manufacturing capabilities. As of October 2023, the company's bond yields are in line with industry averages, reflecting its strong credit rating and stable financial performance. Recent market developments have seen Edwards Lifesciences focus on ESG initiatives, which may influence future bond offerings and align with investor priorities.